AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05803928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: radiofrequency ablation or microwave ablation
Study NCT05803928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: radiofrequency ablation or microwave ablation
Study NCT04681066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-4620 Injectable Emulsion or CM-4620-IE
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
Study NCT04681066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
Study NCT04326465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage
Description: Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
Study NCT06407882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conductive Exercises
Description: Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
Study NCT06407882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
Study NCT06116084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ericksonian Hypnosis
Description: An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
Study NCT06116084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
Study NCT05891366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL0921
Description: Investigational product WAL0921
Study NCT05477498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
Study NCT05477498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
Study NCT05604248 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
Study NCT05891366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product
Study NCT05880355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: Oral inhibitor of NLRP3
Study NCT05880355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo
Study NCT00051090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Administered orally twice daily in doses of 300 mg
Study NCT05833555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MH task-sharing training
Description: Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
Study NCT05833555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MH task-sharing training
Description: Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
Study NCT05833555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision
Description: Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
Study NCT05833555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
Study NCT05833555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
Study NCT05955872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.
Study NCT05146037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 and saline flushing
Description: TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
Study NCT05146037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline flushing
Description: TAVI valves will be flushed with saline only as per IFU.
Study NCT05452317 — intervention group
Intervention type: OTHER
Intervention: Chronic active AMR group
Description: Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
Study NCT05452317 — intervention group
Intervention type: OTHER
Intervention: Non-Chronic active AMR group
Description: Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
Study NCT06391580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactin Acid (PLLA) Based Facial Injectable
Description: Poly-L-lactin Acid (PLLA) Based Facial Injectable
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
Study NCT05196204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk-oriented task training combined with functional electrical stimulation
Description: Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
Study NCT05196204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk-oriented task training alone
Description: The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
Study NCT05866783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrencePrognosticScore
Description: Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
Study NCT05866783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCCRecurrenceDiagnosticScore
Description: Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
Study NCT05239208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement (ONS) Group
Description: Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
Study NCT05239208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Dietary counseling
Study NCT04916431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-6231
Description: Sterile frozen liquid dispersion for injection
Study NCT06243094 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: All antibiotic therapy characteristics are monitored.
Study NCT05848609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Geriatric Assessment
Description: Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
Study NCT05769764 — intervention group
Intervention type: OTHER
Intervention: Archival tissue specimen and immunohistochemistry staining
Description: This is a non-interventional study and no intervention will be administered.
Study NCT05744596 — intervention group
Intervention type: OTHER
Intervention: Incisura biopsy analysis
Description: a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
Study NCT05512052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hannah Cervical Cup (2 mm Delta)
Description: The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
Study NCT05512052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hannah Cervical Cup (4 mm Delta)
Description: The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
Study NCT05512052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hannah Cervical Cup (6 mm Delta)
Description: The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
Study NCT05364216 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
Study NCT04829942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive health behavior
Description: Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
Study NCT05765292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
Study NCT05765292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
Study NCT05364216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
Study NCT05364216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block
Study NCT05364216 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The assessment of cognitive function
Description: Participants were assessed for MMSE and MoCA at the same period as the group C
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
Study NCT04798222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: Participants will receive oral dose of dapagliflozin capsule in fasted condition.
Study NCT06352697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lysate (postbiotic and metabiotc)
Description: Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
Study NCT06352697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06260605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Nursing students learning about diabetes complications
Study NCT06345599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
Study NCT06345599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
Description: GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
Study NCT06345599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
Description: Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
Study NCT06189248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness intervention
Description: Teaching personal and social resourcefulness skills.
Study NCT05031572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dietary intervention
Description: Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
Study NCT04489537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MarzAA
Description: A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
Study NCT04489537 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MarzAA
Description: A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
Study NCT06376929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral carbohydrate containing fluid
Description: administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
Study NCT06376929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral carbohydrate containing fluid
Description: administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting